ArticleThe Journal of international medical research2025
The role of formin-like protein 1 in pancreatic cancer and its specific effects on immunity.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo investigate the functions and immunological implication of formin-like protein 1 in pancreatic cancer.MethodsA multitude of public datasets and an in-house cohort were used to assess the clinical relevance and the immunological relevance of formin-like protein 1 in pancreatic cancer. Subsequently, in vitro assays were conducted to evaluate the biological roles of formin-like protein 1 in pancreatic cancer and its effects on immunity.ResultsThe expression of formin-like protein 1 was elevated in pancreatic cancer tissues and linked to a poor prognosis in pancreatic cancer. In vitro assays showed that elevated expression of formin-like protein 1 promoted pancreatic cancer progression. Moreover, formin-like protein 1 was linked to an inflamed tumor microenvironment and mediated epithelial-mesenchymal transition and programmed cell death 1 ligand 1 expression in pancreatic cancer.ConclusionsFormin-like protein 1 is a biomarker of an inflamed tumor microenvironment and positively modulates epithelial-mesenchymal transition and programmed cell death 1 ligand 1 expression in pancreatic cancer, which could be utilized as a novel target for antitumor immunity for more in-depth studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.